SpringerLink
Log in

Newer Antiseizure Medications and Suicidality: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background

The association between antiseizure medications (ASMs) and suicidality remains controversial. Analyses of additional datasets are needed to further elucidate the complex relationship between antiseizure medications and suicidality.

Objective

The aim of this study was to compare the safety profile of newer ASMs with older ASMs through an analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, with a focus on suicidality.

Methods

We queried over 17 million reports in the FAERS database from 2012 to 2021 and identified cases involving ASMs. After removing incomplete and duplicate reports, the study cohort consisted of lacosamide (n = 7593), perampanel (n = 1813), clobazam (n = 3827), brivaracetam (n = 1166), and vigabatrin (n = 5293) compared with a control group of older ASMs (topiramate, lamotrigine, valproic acid, carbamazepine, levetiracetam; n = 71,535). Cases of suicidality (completed suicide, suicidal ideation, attempted suicide, suicidal behavior, suicidal depression) were identified in each group. Adjusted (age and sex) odds ratios (aOR) and associated 95% confidence intervals (CI) were calculated using logistic regression analysis for each new drug when compared with the control group of older ASM drugs.

Results

A total of 6309 cases of suicidality were identified among reports with ASMs. Most reports were sourced from healthcare professionals (5516, 87.4%). The proportion of reports involving suicidality were 210/7593 (2.8%) for lacosamide, 185/1813 (10.2%) for perampanel, 108/3827 (2.8%) for clobazam, 57/1166 (4.9%) for brivaracetam, 14/5293 (0.3%) for vigabatrin, and 5735/71,535 (8.0%) for older ASMs. Compared with older ASMs, the aOR for suicidality was 0.33 (95% CI 0.28–0.38) for lacosamide, 1.34 (95% CI 1.15–1.56) for perampanel, 0.35 (95% CI 0.29–0.43) for clobazam, 0.60 (95% CI 0.45–0.77) for brivaracetam, and 0.03 (95% CI 0.02–0.05) for vigabatrin.

Conclusion

When compared with older ASMs, four newer ASMs (lacosamide, clobazam, brivaracetam, and vigabatrin) were found to have significantly lower odds of suicidality, while perampanel was found to significantly increase the odds of suicidality. Pronounced variability (greater than 30 fold) in the proportion of FAERS reports associated with suicidality among the drugs studied was identified. The results of this case control study of FDA adverse event reports spanning 10 years and 6309 cases of suicidality expand our understanding of the safety profile of newer ASMs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mesraoua B, Deleu D, Hassan AH, et al. Dramatic outcomes in epilepsy: depression, suicide, injuries, and mortality. Curr Med Res Opin. 2020;36(9):1473–80.

    Article  PubMed  Google Scholar 

  2. Kanner AM. Suicidality and epilepsy: a complex relationship that remains misunderstood and underestimated. Epilepsy Curr. 2009;9(3):63–6.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Tian N, Cui W, Zack M, Kobau R, Fowler KA, Hesdorffer DC. Suicide among people with epilepsy: a population-based analysis of data from the US National Violent Death Reporting System, 17 states, 2003–2011. Epilepsy Behav. 2016;61:210–7.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Abraham N, Buvanaswari P, Rathakrishnan R, et al. A meta-analysis of the rates of suicide ideation, attempts and deaths in people with epilepsy. Int J Environ Res Public Health. 2019;16(8):1451.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Fiest KM, Dykeman J, Patten SB, et al. Depression in epilepsy: a systematic review and meta-analysis. Neurology. 2013;80(6):590–9.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol. 2007;6(8):693–8.

    Article  PubMed  Google Scholar 

  7. Jones JE, Hermann BP, Barry JJ, Gilliam FG, Kanner AM, Meador KJ. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav. 2003;4(Suppl 3):S31–8.

    Article  PubMed  Google Scholar 

  8. US Department of Health and Human Services. Statistical Review and Evaluation: Antiepileptic Drugs and Suicidality. Accessed February 22, 2022. https://www.fda.gov/files/drugs/published/Statistical-Review-and-Evaluation--Antiepileptic-Drugs-and-Suicidality.pdf

  9. Kanner AM, Bicchi MM. Antiseizure medications for adults with epilepsy: a review. JAMA. 2022;327(13):1269–81.

    Article  CAS  PubMed  Google Scholar 

  10. Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs i: treatment of new-onset epilepsy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2018;91(2):74–81.

    Article  CAS  PubMed  Google Scholar 

  11. Löscher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: From bromide salts to cenobamate and beyond [published correction appears. CNS Drugs. 2021;35(9):935–63.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Besag FMC, Vasey MJ. Neurocognitive effects of antiseizure medications in children and adolescents with epilepsy. Paediatr Drugs. 2021;23(3):253–86.

    Article  PubMed  Google Scholar 

  13. Hakami T. Neuropharmacology of antiseizure drugs. Neuropsychopharmacol Rep. 2021;41(3):336–51.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Klein P, Devinsky O, French J, et al. Suicidality risk of newer antiseizure medications: a meta-analysis. JAMA Neurol. 2021;78(9):1118–27.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Brown E. Medical Dictionary for Regulatory Activities (MedDRA). Pharmacovigilance. John Wiley & Sons, Ltd, NJ; 2006;168-83

  16. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070093.htm. Published October 22, 2021. Accessed August 7, 2022.

  17. Food and Drug Administration. National Drug Code Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory Published July 22, 2022. Accessed August 7, 2022.

  18. GraphPad Prism version 9.3.0 for Windows, GraphPad Software, San Diego, California, USA, www.graphpad.com

  19. Center for Drug Evaluation and Research. Application number: 205836Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205836Orig1s000_205837Orig1s000_205838Orig1s000MedR.pdf Accessed September 10, 2022.

  20. Center for Drug Evaluation and Research. Application number: 202834Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202834Orig1s000MedR.pdf Accessed September 10, 2022.

  21. Center for Drug Evaluation and Research. Application number: 203993Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205836Orig1s000_205837Orig1s000_205838Orig1s000MedR.pdf Accessed September 10, 2022

  22. Center for Drug Evaluation and Research. Application number: 022255Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022255Orig1s000Approv.pdf Accessed September 10, 2022.

  23. Center for Drug Evaluation and Research. Application number: 22-006. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022006s000_MedR.pdf Accessed September 10, 2022.

  24. Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. Behav Neurol. 2018;2018:2064027.

    PubMed  PubMed Central  Google Scholar 

  25. Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, Schneeweiss S. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303:1401–9.

    Article  CAS  PubMed  Google Scholar 

  26. VanCott AC, Cramer JA, Copeland LA, Zeber JE, Steinman MA, Dersh JJ, et al. Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system. BMC Med. 2010;8:4.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ferrer P, Ballarín E, Sabaté M, et al. Antiepileptic drugs and suicide: a systematic review of adverse effects. Neuroepidemiology. 2014;42(2):107–20.

    Article  PubMed  Google Scholar 

  28. Hesdorffer DC, Ishihara L, Webb DJ, Mynepalli L, Galwey NW, Hauser WA. Occurrence and recurrence of attempted suicide among people with epilepsy. JAMA Psychiat. 2016;73(1):80–6.

    Article  Google Scholar 

  29. Friedman D, Spruill TM, Liu H, et al. Depressive symptoms and suicidality among individuals with epilepsy enrolled in self-management studies: results from the US centers for disease control and prevention Managing Epilepsy Well (MEW) network. Epilepsy Behav. 2018;87:235–40.

    Article  PubMed  Google Scholar 

  30. Dreier JW, Pedersen CB, Gasse C, Christensen J. Antiepileptic drugs and suicide: Role of prior suicidal behavior and parental psychiatric disorder. Ann Neurol. 2019;86(6):951–61.

    Article  PubMed  Google Scholar 

  31. Faught E. Suicidality: once again, don’t blame the drug class. Epilepsy Curr. 2022;22(1):28–30.

    Article  Google Scholar 

  32. Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia. 2013;54(1):199–203.

    Article  CAS  PubMed  Google Scholar 

  33. Stergiopoulos S, Brown CA, Felix T, Grampp G, Getz KA. A survey of adverse event reporting practices among US healthcare professionals. Drug Saf. 2016;39(11):1117–27.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16(4):359–65.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, Binghamton University School of Pharmacy & Pharmaceutical Sciences, Johnson City, NY, 13790, USA

    Emily E. Leppien, Bennett J. Doughty & Kenneth L. McCall

  2. Binghamton University School of Pharmacy & Pharmaceutical Sciences, 96 Corliss Avenue, Johnson City, NY, 13790, USA

    Karyssa L. Hurd & Keira N. Strong

  3. Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, 18510, USA

    Brian J. Piper

  4. Geisinger Center for Pharmacy Innovation and Outcomes, Daville, PA, 17821, USA

    Brian J. Piper

Authors
  1. Emily E. Leppien
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bennett J. Doughty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karyssa L. Hurd
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keira N. Strong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Brian J. Piper
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenneth L. McCall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth L. McCall.

Ethics declarations

Funding

This research received no external funding.

Conflicts of Interest

Dr. Brian J Piper was (2019–21) part of an osteoarthritis research team supported by Pfizer and Eli Lilly. Dr. Piper is part of a medical marijuana research team supported by the Geisinger Academic Clinical Research Center. Dr. Bennett Doughty is a paid speaker of Otsuka’s PsychU platform. The other authors have no conflict of interest to disclose.

Institutional Review Board Statement

The study was approved by the Binghamton University Institutional Review Board. IRB ID# STUDY00003621 June 7, 2022.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Data Availability Statement

A publicly available dataset was analyzed in this study. This data can be found here: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard.

Code Availability

Not applicable.

Author Contributions

All authors were involved in the study conceptualization, development of methodology, and analysis. All authors were involved in writing, reviewing, and editing the manuscript. All authors have read and agreed to the published version of the manuscript.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leppien, E.E., Doughty, B.J., Hurd, K.L. et al. Newer Antiseizure Medications and Suicidality: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Clin Drug Investig 43, 393–399 (2023). https://doi.org/10.1007/s40261-023-01272-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-023-01272-9

Search

Navigation